-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Investors One-year Losses Grow to 62% as the Stock Sheds CN¥1.7b This Past Week
Investors One-year Losses Grow to 62% as the Stock Sheds CN¥1.7b This Past Week
The nature of investing is that you win some, and you lose some. And unfortunately for InnoCare Pharma Limited (HKG:9969) shareholders, the stock is a lot lower today than it was a year ago. To wit the share price is down 62% in that time. We wouldn't rush to judgement on InnoCare Pharma because we don't have a long term history to look at. Furthermore, it's down 41% in about a quarter. That's not much fun for holders. However, one could argue that the price has been influenced by the general market, which is down 17% in the same timeframe.
Given the past week has been tough on shareholders, let's investigate the fundamentals and see what we can learn.
View our latest analysis for InnoCare Pharma
InnoCare Pharma wasn't profitable in the last twelve months, it is unlikely we'll see a strong correlation between its share price and its earnings per share (EPS). Arguably revenue is our next best option. Shareholders of unprofitable companies usually expect strong revenue growth. Some companies are willing to postpone profitability to grow revenue faster, but in that case one does expect good top-line growth.
InnoCare Pharma grew its revenue by 1,061% over the last year. That's a strong result which is better than most other loss making companies. Meanwhile, the share price slid 62%. Typically a growth stock like this will be volatile, with some shareholders concerned about the red ink on the bottom line (that is, the losses). Generally speaking investors would consider a stock like this less risky once it turns a profit. But when do you think that will happen?
The graphic below depicts how earnings and revenue have changed over time (unveil the exact values by clicking on the image).
SEHK:9969 Earnings and Revenue Growth September 28th 2022We like that insiders have been buying shares in the last twelve months. Even so, future earnings will be far more important to whether current shareholders make money. So we recommend checking out this free report showing consensus forecasts
A Different Perspective
We doubt InnoCare Pharma shareholders are happy with the loss of 62% over twelve months. That falls short of the market, which lost 23%. That's disappointing, but it's worth keeping in mind that the market-wide selling wouldn't have helped. With the stock down 41% over the last three months, the market doesn't seem to believe that the company has solved all its problems. Basically, most investors should be wary of buying into a poor-performing stock, unless the business itself has clearly improved. It's always interesting to track share price performance over the longer term. But to understand InnoCare Pharma better, we need to consider many other factors. Even so, be aware that InnoCare Pharma is showing 2 warning signs in our investment analysis , you should know about...
There are plenty of other companies that have insiders buying up shares. You probably do not want to miss this free list of growing companies that insiders are buying.
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on HK exchanges.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
投资的本质是你赢了一些,你输了一些。不幸的是 诺诚健华制药有限公司 (HKG: 9969) 股东们,今天的股票比一年前低了很多。顺便说一句话,那段时间股价下跌了62%。我们不会急于对InnoCare Pharma做出判断,因为我们没有长期的历史可看。此外,它在大约一个季度内下降了41%。对于持有者来说,这没什么好玩的。但是,有人可能会争辩说,价格受到了整体市场的影响,在同一时期内下跌了17%。
鉴于过去一周对股东来说很艰难,让我们调查一下基本面,看看我们能学到什么。
查看我们对诺诚健华制药的最新分析
InnoCare Pharma在过去十二个月中没有盈利,我们不太可能看到其股价与每股收益(EPS)之间存在很强的相关性。可以说,收入是我们的下一个最佳选择。无利可图公司的股东通常期望强劲的收入增长。一些公司愿意推迟盈利以更快地增加收入,但在这种情况下,人们确实预计收入将保持良好的增长。
去年,诺诚健华制药的收入增长了1,061%。这是一个强劲的业绩,比大多数其他亏损公司都要好。同时,股价下跌了62%。通常,像这样的成长型股票会波动不定,一些股东担心底线上的红色墨水(即亏损)。一般来说,投资者会认为这样的股票一旦盈利,风险就会降低。但是你认为什么时候会发生?
下图描述了收入和收入随时间推移而发生的变化(点击图片即可显示确切的数值)。
SEHK: 9969 收益与收入增长 2022 年 9 月 28 日我们喜欢内部人士在过去十二个月中一直在购买股票。即便如此,未来的收益对于当前股东能否赚钱要重要得多。所以我们建议你看看这个 免费的 显示共识预测的报告
不同的视角
我们怀疑诺诚健华制药的股东对十二个月内亏损62%感到满意。这低于市场,后者下跌了23%。这令人失望,但值得记住的是,全市场的抛售无济于事。该股在过去三个月中下跌了41%,市场似乎并不认为该公司已经解决了所有问题。基本上,除非业务本身有了明显改善,否则大多数投资者应该谨慎买入表现不佳的股票。长期跟踪股价表现总是很有趣。但是,为了更好地了解诺诚健华制药,我们需要考虑许多其他因素。即便如此,请注意诺诚健华制药正在表现出色 我们的投资分析中有两个警告信号 ,你应该知道...
还有很多其他公司有内部人士买入股票。你可能这样做 不 想错过这个 免费的 内部人士正在收购的成长型公司名单。
请注意,本文引用的市场回报反映了目前在香港交易所交易的股票的市场加权平均回报。
对这篇文章有反馈吗?对内容感到担忧? 取得联系 直接和我们联系。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St 的这篇文章本质上是一般性的。 我们仅使用不偏不倚的方法根据历史数据和分析师预测提供评论,我们的文章并非旨在提供财务建议。 它不构成买入或卖出任何股票的建议,也没有考虑您的目标或财务状况。我们的目标是为您提供由基本面数据驱动的长期重点分析。请注意,我们的分析可能未将最新的价格敏感型公司公告或定性材料考虑在内。简而言之,华尔街对上述任何股票都没有头寸。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧